7 completed. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
| Phase 2 | 1 | Completed 1 |
Follow Safety: new trials by email Literature Review of Safety trials Research Report on Safety
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents E4/DRSP 15/3 mg combined tablet - Safety | Phase 3 | Completed | Estetra | 145 | 2020-12-28 | 2023-12-22 |
| Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B Recombinant Hepatitis B + DTP-HB-Hib, Hep B + Pentabio (registered) - Immunogenicity, Safety | Phase 3 | Completed | PT Bio Farma | 220 | 2020-10-13 | 2022-01-18 |
| Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants. Test product, Control product - Subjects in Need of a Human Milk Fortifier (HMF), Growth | Phase 2 / Phase 3 | Completed | Nutricia Research | 207 | 2018-03-08 | 2024-09-26 |
| Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age ATX-101, Placebo - Moderate to Severe Convexity of Submental Fat, Safety | Phase 3 | Completed | Kythera Biopharmaceuticals | 55 | 2014-04-01 | 2020-02-17 |
| Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat Deoxycholic Acid, Placebo - Moderate to Severe Convexity of Submental Fat, Safety | Phase 3 | Completed | Kythera Biopharmaceuticals | 93 | 2014-01-01 | 2020-02-17 |
| Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide - Safety | Phase 3 | Completed | Takeda | 153 | 2011-03-01 | 2013-12-13 |
| Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose. 13-valent pneumococcal conjugate vaccine - 13-valent Pneumococcal Vaccine, Immunization | Phase 3 | Completed | Pfizer | 263 | 2010-04-01 | 2012-02-08 |
Hypertension (1) · Kidney Diseases (1) · Renal Insufficiency (1)
Cardiovascular Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1) · Vascular Diseases (1)
Deoxycholic Acid (2) · Chlorthalidone (1) · Control Groups (1) · Hydrochlorothiazide (1) · Olmesartan Medoxomil (1) · azilsartan medoxomil (1)
Kythera Biopharmaceuticals (2) · Estetra (1) · Nutricia Research (1) · PT Bio Farma (1) · Pfizer (1) · Takeda (1)
France (2) · Germany (2) · Latvia (2) · Netherlands (2) · Poland (2) · United States (2) · Bulgaria (1) · Estonia (1) · Finland (1) · Georgia (1) · Indonesia (1) · Lithuania (1) · Slovakia (1) · Sweden (1) · Ukraine (1)
Frederick Beddingfield, III, MD, PhD (2) · Eddy Fadliyana (1)
2019 (1)